Loading patent…
AssigneeRenovo Limited
InventorsMark William James Ferguson, Hugh Laverty, Nicholas Occleston, Sharon O'Kane, Kerry Nield
Estimating the term…
Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. The methods and medicaments of the invention are suitable for use in the prevention, reduction or inhibition of scarring arising as a result of healing of a wound, or scarring associated with a fibrotic disorder. The methods and medicaments disclosed are of particular use in preventing, reducing or inhibiting scarring of the skin.
WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring.
WNT3A, or a therapeutically effective fragment or derivative thereof, according to any preceding claim, for use wherein the scarring occurs in a tissue selected from the group consisting of:
WNT3A, or a therapeutically effective fragment or derivative thereof, according to any preceding claim, for use wherein the scarring is associated with a fibrotic disorder.
WNT3A, or a therapeutically effective fragment or derivative thereof, according to any preceding claim, for use wherein the medicament is for use in the prevention, reduction or inhibition of scarring of the skin.
WNT3A, or a therapeutically effective fragment or derivative thereof, according to any preceding claim, for use wherein the medicament is a topical medicament.
WNT3A, or a therapeutically effective fragment or derivative thereof, according to any preceding claim, for use wherein the medicament is an injectable solution.
WNT3A according to any preceding claim, for use as a medicament for the prevention, reduction or inhibition of scarring.
WNT3A, or a therapeutically effective fragment or derivative thereof, according to any preceding claim, for use wherein the medicament provides approximately 1 ng of WNT3A, or a fragment or derivative thereof, per centimetre of wound or fibrosis.
A method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.
Dependencies are inferred from the claim text.